Literature DB >> 12910525

Characterization of the neoplastic phenotype in the familial atypical multiple-mole melanoma-pancreatic carcinoma syndrome.

Stephen J Rulyak1, Teresa A Brentnall, Henry T Lynch, Melissa A Austin.   

Abstract

BACKGROUND: Previous studies suggest that the familial atypical multiple-mole melanoma (FAMMM) syndrome may predispose affected families to nonmelanoma carcinomas, including adenocarcinoma of the pancreas. It has been found that many of these families harbor mutations in the CDKN2A gene on chromosome 9p21. The phenotypic expression of CDKN2A mutations in these families has not been characterized fully.
METHODS: The authors studied eight families that appeared to inherit multiple nevi, cutaneous melanomas, and pancreatic carcinomas in association with a CDKN2A germline mutation. The expression of disease within these families was examined, and segregation ratios were estimated to assess the patterns of inheritance according to various definitions of phenotype.
RESULTS: Either multiple nevi or pancreatic carcinoma was diagnosed in 53% of first-degree relatives of the probands. The offspring of parents affected with multiple nevi, melanoma, or pancreatic carcinoma were significantly more likely to be affected themselves compared with the offspring of unaffected parents (48.9% vs. 16.7%; P = 0.004).
CONCLUSIONS: The current results provide additional evidence that multiple nevi, melanoma, or pancreatic carcinoma may be inherited as autosomal-dominant traits in families known to harbor CDKN2A mutations. Other malignancies may be a part of the phenotype in these families, although this hypothesis requires additional study. Copyright 2003 American Cancer Society.DOI 10.1002/cncr.11562

Entities:  

Mesh:

Year:  2003        PMID: 12910525     DOI: 10.1002/cncr.11562

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  14 in total

Review 1.  [Prophylactic pancreas surgery].

Authors:  P Langer; M Rothmund; D K Bartsch
Journal:  Chirurg       Date:  2006-01       Impact factor: 0.955

2.  Novel targeted therapies for the treatment of metastatic melanoma.

Authors:  Ragini Kudchadkar
Journal:  Ochsner J       Date:  2010

3.  Germline Variation at CDKN2A and Associations with Nevus Phenotypes among Members of Melanoma Families.

Authors:  Nicholas J Taylor; Nandita Mitra; Alisa M Goldstein; Margaret A Tucker; Marie-Françoise Avril; Esther Azizi; Wilma Bergman; D Timothy Bishop; Brigitte Bressac-de Paillerets; William Bruno; Donato Calista; Lisa A Cannon-Albright; Francisco Cuellar; Anne E Cust; Florence Demenais; David E Elder; Anne-Marie Gerdes; Paola Ghiorzo; Thais C Grazziotin; Johan Hansson; Mark Harland; Nicholas K Hayward; Marko Hocevar; Veronica Höiom; Christian Ingvar; Maria Teresa Landi; Gilles Landman; Alejandra Larre-Borges; Sancy A Leachman; Graham J Mann; Eduardo Nagore; Håkan Olsson; Jane M Palmer; Barbara Perić; Dace Pjanova; Antonia Pritchard; Susana Puig; Nienke van der Stoep; Karin A W Wadt; Linda Whitaker; Xiaohong R Yang; Julia A Newton Bishop; Nelleke A Gruis; Peter A Kanetsky
Journal:  J Invest Dermatol       Date:  2017-08-19       Impact factor: 8.551

Review 4.  Hereditary melanoma: Update on syndromes and management: Genetics of familial atypical multiple mole melanoma syndrome.

Authors:  Efthymia Soura; Philip J Eliades; Kristen Shannon; Alexander J Stratigos; Hensin Tsao
Journal:  J Am Acad Dermatol       Date:  2016-03       Impact factor: 11.527

Review 5.  Management strategies for patients with hereditary pancreatic cancer.

Authors:  Teresa A Brentnall
Journal:  Curr Treat Options Oncol       Date:  2005-09

6.  Effect of a detailed family history of melanoma on risk for other tumors: a cohort study based on the nationwide Swedish Family-Cancer Database.

Authors:  Tianhui Chen; Mahdi Fallah; Elham Kharazmi; Jianguang Ji; Kristina Sundquist; Kari Hemminki
Journal:  J Invest Dermatol       Date:  2013-11-05       Impact factor: 8.551

7.  Novel presentation of a familial pancreatic cancer syndrome.

Authors:  Ajay V Maker; James A Warth; Michael J Zinner
Journal:  J Gastrointest Surg       Date:  2008-12-17       Impact factor: 3.452

Review 8.  Selection criteria for genetic assessment of patients with familial melanoma.

Authors:  Sancy A Leachman; John Carucci; Wendy Kohlmann; Kimberly C Banks; Maryam M Asgari; Wilma Bergman; Giovanna Bianchi-Scarrà; Teresa Brentnall; Brigitte Bressac-de Paillerets; William Bruno; Clara Curiel-Lewandrowski; Femke A de Snoo; Tadeusz Debniak; Marie-France Demierre; David Elder; Alisa M Goldstein; Jane Grant-Kels; Allan C Halpern; Christian Ingvar; Richard F Kefford; Julie Lang; Rona M MacKie; Graham J Mann; Kurt Mueller; Julia Newton-Bishop; Håkan Olsson; Gloria M Petersen; Susana Puig; Darrell Rigel; Susan M Swetter; Margaret A Tucker; Emanuel Yakobson; John A Zitelli; Hensin Tsao
Journal:  J Am Acad Dermatol       Date:  2009-10       Impact factor: 11.527

Review 9.  Malignant melanoma in the 21st century: the emerging molecular landscape.

Authors:  Aleksandar Sekulic; Paul Haluska; Arlo J Miller; Josep Genebriera De Lamo; Samuel Ejadi; Jose S Pulido; Diva R Salomao; Erik C Thorland; Richard G Vile; David L Swanson; Barbara A Pockaj; Susan D Laman; Mark R Pittelkow; Svetomir N Markovic
Journal:  Mayo Clin Proc       Date:  2008-07       Impact factor: 7.616

10.  Molecular markers of tumor progression in melanoma.

Authors:  Joshua Rother; Dan Jones
Journal:  Curr Genomics       Date:  2009-06       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.